Lipid News

Unconventional phosphoinositide synthesis

Greg Fairn Jayatee Ray
By Greg Fairn and Jayatee Ray
Nov. 29, 2022

Salmonella and Shigellabacteria cause or contribute to human diseases ranging from acute food poisoning to life-threatening typhoid fever and gall bladder cancer. Both are on a World Health Organization list of priority pathogens for developing new antibiotics. To help combat the effects of these bacteria, our lab is studying the way they synthesize the tiny lipids known as 3-phosphoinositides to hijack host.

When cells are invaded by Salmonella (pink), the lipid PI3,4P<sub>2</sub> (light blue) is very intense around the bacteria.
Greg Fairn and Glenn Walpole
When cells are invaded by Salmonella (pink), the lipid PI3,4P2 (light blue) is very intense around the bacteria.

These two bacteria can inject bacterial proteins called effectors into target human cells, allowing them to acquire nutrients and reproduce in the cell. Researchers have described one such effector in Salmonella, SopB, and its homolog in Shigella, IpgD, as phosphatidylinositol 4,5-bisphosphate, or PI(4,5)P2, phosphatases. These phosphatases deplete PI4,5P2, an important lipid in human cells for proper actin dynamics, endocytosis and ion channel regulation.

Although they deplete PI4,5P2, these bacterial phosphatases increase two other phosphoinositides, PI3,4P2 and PI3,4,5P3. Production of these two lipids stimulates the activation of small GTPases, including Rac1 and Cdc42, that induce robust and localized plasma membrane ruffling near the site of bacterial attachment. Ultimately, the bacteria invade and hijack the host cells. Production of PI3,4P2 and PI3,4,5P3 also promotes the survival of the now-infected cell by activating the serine/threonine protein kinase Akt and other downstream pathways.

How could a phosphatase seemingly increase the levels of phosphoinositides typically produced by kinases? For years, researchers thought that SopB and IpgD somehow were activating multiple host phosphoinositide 3-kinases, or PI3Ks. Inhibiting individual PI3Ks did not prevent the function of the effectors and the production of PI3,4P2 and PI3,4,5P3. Could the ability to produce PI3,4P2 and PI3,4,5P3 be intrinsic to SopB and IpgD? In support of this notion, researchers established that the catalytic cysteine residue in the active site was required for both the reduction of PI4,5P2 and the production of PI3,4P2/PI3,4,5P3.

SopB and IpgD are homologs of human phosphoinositide phosphatases, such as synaptojanin and INPP4B, that are related to the larger family of protein tyrosine phosphatases. These phosphatases contain active cysteine residues, and as part of the enzymatic cycle, there is a cysteine–phosphate intermediate that then is hydrolyzed by water. SopB and IpgD operate on the membrane surface, raising the possibility that another lipid, not water, could attack the cysteine–phosphate intermediate. In this situation, the effector would behave as a phosphotransferase and not a phosphatase.

Armed with this hypothesis, we demonstrated that SopB could generate PI3,4,5P3/PI3,4P2 in a test tube when supplied with only PI4,5P2 as a substrate. SopB is a very active phosphatase; if given enough time, the phosphoinositides are reduced to PI and the free inorganic phosphate. Given the redundancy of PI3Ks in mammalian cells, we used baker’s yeast, which naturally lacks class I and II PI3Ks and remains viable even when the sole class III PI3K is inactivated. When we introduced SopB into these mutant yeast cells, which contain ample amounts of PI4,5P2 but no PI3K activity, PI3,4P2 was formed.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Greg Fairn
Greg Fairn

Greg Fairn is a professor of pathology at Dalhousie University.

Jayatee Ray
Jayatee Ray

Jayatee Ray is a graduate student studying pathology at Dalhousie University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Calcium channel linked to cancer drug resistance
Journal News

Calcium channel linked to cancer drug resistance

June 12, 2025

Researchers discover a protein associated with carboplatin-resistant retinoblastoma, suggesting this protein could be a promising therapeutic target. Read more about this recent Journal of Biological Chemistry paper.

Host fatty acids enhance dengue virus infectivity
Journal News

Host fatty acids enhance dengue virus infectivity

June 12, 2025

Researchers in Germany find that viral replication depends on host enzymes that synthesize lipids, revealing potential metabolic targets for antiviral intervention. Read more about this recent Journal of Biological Chemistry paper.

Antibodies inhibit hyperactive protein disposal
Journal News

Antibodies inhibit hyperactive protein disposal

June 12, 2025

Researchers at the University of California, San Francisco, identify an enzyme inhibitor, offering new tools to study diseases like cystic fibrosis, neurodegeneration and cancer. Read more about this recent Journal of Biological Chemistry paper.

Scientists find unexpected correlation between age and HDL-C levels
Journal News

Scientists find unexpected correlation between age and HDL-C levels

June 3, 2025

In a 30-year multicenter study, researchers determined what factors predict HDL-C concentration. In their analysis, they found that HDL-C levels grew with increasing age and physical activity.

Butter, olive oil, coconut oil — what to choose?
Journal News

Butter, olive oil, coconut oil — what to choose?

May 28, 2025

Depending on the chain length and origin of the fat, regular fat consumption changes the specific makeup of fats in bloodstream and affect mild to severe cholesterol patterns. Read about this recent Journal of Lipid Research study.

Computational tool helps scientists create novel bug sprays
Journal News

Computational tool helps scientists create novel bug sprays

May 20, 2025

Rapid discovery of mosquito repellent compounds is enabled through a novel screening platform that combines both computational modeling and functional screening.